In the Claims:

1. (Currently Amended) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof in which:

X is selected from the group consisting of oxygen and NR^2;

Y is ~~selected from the group consisting of~~ CH ~~and nitrogen~~;

R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylOC_{1-3}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-7}cycloalkyl substituted by C_{1-3}alkyl or C_{1-3}alkoxy, C_{4-12}bridged cycloalkyl, and $A(CR^6R^7)_n$ ~~and $B(CR^6R^7)_n$~~;

R^2 is selected from the group consisting of H and C_{1-6}alkyl; ~~or~~

~~R1 and R2, together with the nitrogen atom to which they are attached form a 4-8 membered saturated heterocyclic ring, or a 5-membered heteroaryl ring which is unsubstituted or substituted by one R8;~~

R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;

R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^9CONH;

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylO_2C, halogen, cyano, $(C_{1-3}alkyl)_2NCO$, C_{1-3}alkyl$S$ and C_{1-3}alkylO_2S;

R^6 and R^7 are independently selected from H and C_{1-6}alkyl;

A is an ~~unsubstituted 5- or 6-membered heteroaryl or an~~ unsubstituted 6-membered aryl, ~~or a 5- or 6-membered heteroaryl~~ or a 6-membered aryl substituted by one or more R^8;

R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and C_{1-6}alkylSO_2;

~~B is selected from the group consisting of~~



and where

~~) defines the point of attachment of the ring;~~

R^9 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylOC_{1-6}alkyl, phenyl, HO_2CC_{1-6}alkyl, C_{1-6}alkyl$OCOC_{1-6}$alkyl, C_{1-6}alkylOCO, H_2NC_{1-6}alkyl, C_{1-6}alkyl$OCONHC_{1-6}$alkyl and C_{1-6}alkyl$CONHC_{1-6}$alkyl;

R^{10} is selected from the group consisting of H and halogen; and

n is 0 to 4.

2. (Currently Amended) The compound of claim 1 ~~A compound of formula (IA)~~



(IA)

or a pharmaceutically acceptable salt thereof, wherein ~~in which:~~

~~X is selected from the group consisting of oxygen and NR^2;~~

~~Y is selected from the group consisting of CH and nitrogen;~~

R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylOC_{1-3}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-12}bridged cycloalkyl, and $A(CR^6R^7)_n$ ~~and $B(CR^6R^7)_n$~~;

~~R^2 is selected from the group consisting of H and C_{1-6}alkyl; or~~

~~R^1 and R^2, together with the nitrogen atom to which they are attached form a 4-8 membered saturated heterocyclic ring;~~

~~R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;~~

~~R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^9CONH;~~

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, halogen, cyano, $(C_{1-3}alkyl)_2NCO$, C_{1-3}alkylS and $C_{1-3}alkylO_2S$;

~~R^6 and R^7 are independently selected from H or C_{1-6}alkyl;~~

~~A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R^8;~~

~~R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and $C_{1-6}alkylSO_2$;~~

~~B is selected from the group consisting of~~



and where

~~) defines the point of attachment of the ring;~~

~~R^9 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, $C_{1-6}alkylOC_{1-6}$alkyl, phenyl, HO_2CC_{1-6}alkyl, $C_{1-6}alkylOCOC_{1-6}$alkyl, $C_{1-6}alkylOCO$, H_2NC_{1-6}alkyl, $C_{1-6}alkylOCONHC_{1-6}$alkyl and $C_{1-6}alkylCONHC_{1-6}$alkyl;~~

~~R^{10} is selected from the group consisting of H and halogen; and~~

~~n is 0 to 4~~.

3. (Currently Amended) The compound of claim 1 ~~A compound of formula (IC)~~



(IC)

or a pharmaceutically acceptable salt thereof wherein ~~in which:~~

~~X is selected from the group consisting of oxygen and NR^2;~~

~~Y is selected from the group consisting of CH and nitrogen;~~

~~R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylOC_{1-3}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-7}cycloalkyl substituted by C_{1-3}alkyl or C_{1-3}alkoxy, C_{4-12}bridged cycloalkyl, and A$(CR^6R^7)_n$ and B$(CR^6R^7)_n$;~~

~~R^2 is selected from the group consisting of H and C_{1-6}alkyl; or~~

~~R^1 and R^2, together with the nitrogen atom to which they are attached form a 4-8 membered saturated heterocyclic ring, or a 5-membered heteroaryl ring which is unsubstituted or substituted by one R^8;~~

~~R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;~~

~~R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^9CONH;~~

~~R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylO_2C, halogen, cyano, $(C_{1-3}alkyl)_2NCO$, C_{1-3}alkyl$S$ and C_{1-3}alkylO_2S;~~

~~R^6 and R^7 are independently selected from H or C_{1-6}alkyl;~~

~~A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R^8;~~

~~R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and C_{1-6}alkylSO_2;~~

~~B is selected from the group consisting of~~



and where

) defines the point of attachment of the ring;

~~R^9 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylOC_{1-6}alkyl, phenyl, HO_2CC_{1-6}alkyl, C_{1-6}alkylOCOC_{1-6}alkyl, C_{1-6}alkylOCO_2, H_2NC_{1-6}alkyl, C_{1-6}alkylO$CONHC_{1-6}$alkyl and C_{1-6}alkyl$CONHC_{1-6}$alkyl;~~

~~R^{10} is selected from the group consisting of H and halogen; and~~

n is 1 to 4.

4. (Currently Amended) A compound as claimed in claim 1 wherein:

X is oxygen;

Y is CH;

R^1 is $A(CR^6R^7)_n$;

R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;

R^4 is C_{1-6}alkyl;

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylO_2C, halogen, and C_{1-3}alkylS;

A is an ~~unsubstituted 5- or 6-membered heteroaryl or an~~ unsubstituted 6-membered aryl, or ~~a 5- or 6-membered heteroaryl or~~ a 6-membered aryl substituted by one or more R^8;

R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, and C_{1-6}alkoxy substituted by one or more F;

R^{10} is selected from the group consisting of H and halogen; and

n is 0.

5. (Canceled)

6. (Previously Presented) A compound selected from the group consisting of:

~~4-ethyl-6-[4-(methylsulfonyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)-2-pyridinamine;~~

~~4-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~4-(6-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino}-4-ethyl-2-pyridinyl)benzenesulfonamide;~~

~~N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;~~

~~N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;~~

~~4-[4-methyl-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-2-pyridinyl)benzenesulfonamide;~~

~~4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

N-(cyclohexylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-cyclohexyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

~~2-[4-(methylsulfonyl)phenyl]-6-[(2-pyridinylmethyl)oxy]-4-(trifluoromethyl)pyridine;~~

~~4-methyl-N-[(3-methyl-4-isoxazolyl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~6-[4-(methylsulfonyl)phenyl]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)-2-pyridinamine;~~

N-cycloheptyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-(cis-4-methylcyclohexyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-(1-ethylpropyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

~~N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;~~

~~N-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;~~

~~4-methyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

N-(cyclopentylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine.;

~~N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)amino]-3-pyridinecarbonitrile;~~

~~4-ethyl-2-[[(5-methyl-2-pyridinyl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;~~

~~4-ethyl-2-[[(6-methyl-3-pyridinyl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;~~

~~4-ethyl-2-[[(1-methyl-1H-pyrazol-4-yl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;~~

~~4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[[(4-methyl-1,3-thiazol-2-yl)methyl]amino]-3-pyridinecarbonitrile;~~

~~4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)oxy]-3-pyridinecarbonitrile;~~

~~4-ethyl-N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;~~

~~4-ethyl-2-[[(6-methyl-3-pyridinyl)methyl]oxy]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile; and~~

~~6-[4-(methylsulfonyl)phenyl]-N-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-4-(trifluoromethyl)-2-pyridinamine.~~

7. (Withdrawn and Currently Amended) A process for the preparation of a compound as defined in claim 1 which comprises reacting a compound R^1XH ~~of formula (II)~~, or a protected derivative thereof, with a compound of formula (III)



(III)

where R^1 and X are ~~is~~ as defined in claim 1 and Z is halogen or a sulfonate, and thereafter and if necessary, interconverting a compound of formula (I) into another compound of formula (I), and/or deprotecting a protected derivative of compound of formula (I).

8. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

9. (Canceled)

10. (Canceled).

11. (Withdrawn and Currently Amended) A method of treating an animal subject suffering from a condition selected from pain, fever, or inflammation, which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.

12-13. (Canceled)

14. (Withdrawn) The method according to claim 11, wherein said animal is a human.

15. (Canceled).

16. (Canceled).

17. (Withdrawn and Currently Amended) The method according to claim 11, wherein said condition ~~which is mediated by COX-2~~ is rheumatoid arthritis.

18. (Withdrawn and Currently Amended) The method according to claim 11, wherein said condition ~~which is mediated by COX-2~~ is osteoarthritis.

19. (Withdrawn and Currently Amended) The method according to claim 11, wherein said condition ~~which is mediated by COX-2~~ is chronic or acute pain.

20. (Canceled).

21. (Withdrawn and Currently Amended) The method according to claim 11, wherein said condition ~~which is mediated by COX-2~~ is post-herpetic neuralgia.

22. (Withdrawn and Currently Amended) The method according to claim 11 wherein said condition ~~which is mediated by COX-2~~ is non-specific lower back pain.

23. (Withdrawn and Currently Amended) The method according to claim 11 wherein said condition ~~which is mediated by COX-2~~ is dysmenorrhoea.

24. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 2 in admixture with one or more physiologically acceptable carriers or excipients.

25. (Withdrawn) A method of treating an animal subject suffering from pain, fever, or inflammation which method comprises administering to said subject an effective amount of a compound as claimed in claim 2.

26. (Withdrawn) The method as claimed in claim 25, wherein said animal is a human.

27. (New) N-cyclohexyl-4-(trifluoromethyl)-6-[4-methylsulfonyl)phenyl]pyridine-2-amine or a pharmaceutically acceptable salt thereof.